The landscape for rare diseases in 2024
By definition, rare diseases affect a small number of individuals (fewer than 1 in 2000 people in any WHO region); yet, with more than 7000 types of rare disease in existence, the burden …
The Lancet: Journal Homepage
3 days ago · Prompted by the 20th anniversary of the 1993 World Development Report, a Lancet Commission revisited the case for investment in health and developed a new framework to …
Antimicrobial resistance: a concise update - The Lancet Microbe
Antimicrobial resistance (AMR) is a serious threat to global public health, with approximately 5 million deaths associated with bacterial AMR in 2019. Tackling AMR requires a multifaceted …
Global, regional, and national progress towards the 2030 global ...
Dec 9, 2024 · Based on current levels and past trends, few GNTs will be met by 2030. Major reductions in attributable burden for exclusive breastfeeding and anthropometric indicators …
Pollution and health: a progress update - The Lancet
May 17, 2022 · The Lancet Commission on pollution and health reported that pollution was responsible for 9 million premature deaths in 2015, making it the world's largest environmental …
Antiviral effect of high-dose ivermectin in adults with COVID-19: A ...
Jun 17, 2021 · 45 participants were recruited (30 to IVM and 15 controls) between May 18 and September 9, 2020. There was no difference in viral load reduction between groups but a …
Universal health coverage is a matter of equity, rights, and justice ...
Jul 7, 2023 · Universal health coverage is sometimes misunderstood as a goal to provide all available health services and products free to every person through national health insurance …
Clinical advances and ongoing trials of mRNA vaccines for cancer ...
Years of research exploring mRNA vaccines for cancer treatment in preclinical and clinical trials have set the stage for the rapid development of mRNA vaccines during the COVID-19 …
Mitochondrial disease in adults: recent advances and future …
Mitochondrial diseases are some of the most common inherited neurometabolic disorders, and major progress has been made in our understanding, diagnosis, and treatment of these …
Thrombolysis for acute ischaemic stroke: current status and future ...
Mar 9, 2023 · Alteplase is currently the only approved thrombolytic agent for treatment of acute ischaemic stroke, but interest is burgeoning in the development of new thrombolytic agents for …